BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients

Leukemia

Volumn 24, Issue 8, 2010, Pages 1445-1449

  Marega, M ^a   Piazza, R G ^a   Pirola, A ^a   Redaelli, S ^a   Mogavero, A ^a   Iacobucci, I ^b   Meneghetti, I ^c   Parma, M ^c   Pogliani, E M ^a,c   Gambacorti Passerini, C ^a,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

BCR; BCR ABL; blast crisis; bone marrow precursors

Indexed keywords

BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN;

ARTICLE; BLAST CELL CRISIS; CANCER STEM CELL; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; RNA STABILITY; TRANSCRIPTION REGULATION;

EID: 77955712295     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.101     Document Type: Article

References (15)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
2. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765-767.
3. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
4. Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007; 26: 1456-1466.
5. Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E et al. High levels of the BCR-ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 2007; 110: 994-1003.
6. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
7. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496-506.
8. Zhu QS, Heisterkamp N, Groffen J. Unique organization of the human BCR gene promoter. Nucleic Acids Res 1990; 18: 7119-7125.
9. Shah NP, Witte ON, Denny CT. Characterization of the BCR promoter in Philadelphia chromosome-positive and-negative cell lines. Mol Cell Biol 1991; 11: 1854-1860.
10. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 2002; 99: 11872-11877.
11. Rulcova J, Zmekova V, Zemanova Z, Klamova H, Moravcova J. The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res 2007; 31: 483-491.
12. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemiaFa Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
13. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009; 106: 3925-3929.
14. Gavert N, Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. J Cell Biochem 2007; 102: 820-828.
15. Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A et al. A MAPK/HNRPK pathway controls BCR-ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006; 107: 2507-2516.